Drug licence refused
A decision by the European Medicines Agency (EMA) to refuse a licence for the dementia drug aducanumab has been described as “bitterly disappointing news for people with Alzheimer’s disease.” Alzheimer’s Research UK chief executive Hilary Evans made the comment after the EMA rejected an application by the manufacturer Biogen to distribute the drug across the…